- Home
- CMMB vs TLPH Comparison
CMMB vs TLPH Comparison
Compare CMMB & TLPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CMMB | TLPH |
|---|---|---|
| Founded | 2004 | 2005 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.2M | 37.9M |
| IPO Year | 2023 | 2010 |
Fundamental Metrics
Financial Performance| Metric | CMMB | TLPH |
|---|---|---|
| Price | $1.73 | $0.82 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | ★ $25.00 | $6.00 |
| AVG Volume (30 Days) | 68.9K | ★ 218.9K |
| Earning Date | 03-19-2026 | 04-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 101.67 | N/A |
| EPS | ★ 0.04 | N/A |
| Revenue | N/A | ★ $2,151,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $48.25 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.87 | $0.38 |
| 52 Week High | $3.86 | $1.57 |
Technical Indicators
Market Signals| Indicator | CMMB | TLPH |
|---|---|---|
| Relative Strength Index (RSI) | 48.23 | 43.86 |
| Support Level | $1.48 | $0.76 |
| Resistance Level | $1.85 | $1.03 |
| Average True Range (ATR) | 0.19 | 0.06 |
| MACD | -0.00 | -0.00 |
| Stochastic Oscillator | 22.57 | 34.12 |
Price Performance
Historical ComparisonAbout CMMB Chemomab Therapeutics Ltd.
Chemomab Therapeutics Ltd is a clinical-stage biotech company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin, and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life-threatening fibrotic and inflammatory diseases. It is advancing three Phase 2 clinical trials in parallel for CM-101, treating rare fibrotic conditions.
About TLPH Talphera Inc.
Talphera Inc. is a pharmaceutical company focused on the development and commercialization of therapies for use in medically supervised settings. The Company's nafamostat product candidates include Niyad and LTX-608. Its portfolio consists of nafamostat product candidates and pre-filled syringe product candidates.